Table 5.
Reason for initial treatment with bisphosphonates in patients with bone metastases/lesions, by malignancy type and by country: data from the detailed questionnaire
| Response given (%) | Total (N = 7368) | France (n = 1483) | Germany (n = 1973) | Italy (n = 1427) | Spain (n = 1325) | UK (n = 1160) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | |
| Prevent SREs | 71 | 66 | 66 | 67 | 84 | 87 | 64 | 62 | 65 | 57 | 67 | 61 |
| Treat/prevent pain | 55 | 42 | 57 | 44 | 68 | 72 | 43 | 32 | 49 | 42 | 48 | 29 |
| Prevent new bone metastases/bone lesions | 38 | 47 | 15 | 33 | 69 | 67 | 32 | 47 | 26 | 42 | 26 | 49 |
| Treat bone metastases/lesion at original site(s) | 38 | 36 | 30 | 26 | 59 | 47 | 36 | 38 | 19 | 43 | 33 | 31 |
| Patient's disease has high risk factors | 5 | 7 | 9 | 20 | 1 | 0 | 5 | 6 | 4 | 3 | 10 | 4 |
| End of anti‐tumour treatment | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 3 | 3 | 1 | 2 | 0 |
| Other | 1 | 2 | 3 | 3 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 4 |
HM, haematological malignancy; ST, solid tumour.
Investigators could give more than one response.